Capricor's Deramiocel Navigates FDA Review: A Complex Journey Towards Approval

Capricor's second quarter 2026 earnings call brought some clarity to the regulatory status of its flagship product, deramiocel. The company has been working tirelessly to get this innovative therapy approved by the FDA for the treatment of cardiomyopathy in Duchenne muscular dystrophy (DMD) patients.

However, the outcome of the recent Cellular, Tissue, and Gene Therapies Advisory Committee review was not what Capricor had hoped for. The committee voted three in favor, nine against, with no abstentions, on whether the available evidence provides substantial evidence of effectiveness of deramiocel for this indication. While disappointing, the company remains committed to working with the FDA on the next steps for this program.

CEO Linda Marbán emphasized that Capricor's priority has always been to get deramiocel to those who need it most. In a bid to continue pursuing approval, the company plans to submit an amendment to its BLA that includes additional analyses and data to support a refined indication focused on upper limb skeletal muscle function. This new path forward reflects the primary efficacy endpoint of the HOPE-3 study.

In a separate development, the full results of the HOPE-3 clinical trial were published in The Lancet following extensive peer review. This publication marks an important milestone for the program and the field as a whole.

Capricor's resolve to bring deramiocel to market remains unwavering despite this setback. With the FDA willing to review the proposed amendment, there is still hope for a positive outcome in the coming months. As CEO Marbán noted, 'Our priority is and always has been to get deramiocel to those who need it most.'

The company's commitment to addressing the major unmet need in DMD is clear. With its expertise and dedication, Capricor remains poised to make a significant impact on this devastating disease.

While the road ahead may be complex, one thing is certain: Capricor's pursuit of deramiocel approval will continue unabated. As the company navigates these uncertain waters, it is reassuring to see that it remains committed to its mission and focused on delivering results.